NeuroBo Pharmaceuticals Raises $20 Million from Share Placement
NeuroBo Pharmaceuticals (NRBO) said late Tuesday it has raised about $20 million from its share offering through H.C. Wainwright as its placement agent.
NeuroBo said it plans to use the proceeds for working capital and and general corporate purposes.
The potential additional proceeds to NeuroBo from its clinical milestone-linked Series Warrants, if fully exercised, will be about $50 million and will be used to fund the trial of DA-1726, the clinical-stage biotechnology company.
The shares were up more than 8% in after-hours activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.